Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

Trial Profile

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Letrozole (Primary) ; Ribociclib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOLBC
  • Most Recent Events

    • 15 May 2018 Planned initiation date changed from 1 Feb 2018 to 1 May 2018.
    • 25 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 06 Feb 2018 Planned End Date changed from 1 Nov 2024 to 1 Feb 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top